FMP
NASDAQ
2.66 USD
0.005 (0.188%)
Mr. Nima Farzan M.B.A.
Healthcare
Biotechnology
https://www.kinnate.com
NASDAQ
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinna...
0001797768
US49705R1059
49705R105
103 Montgomery Street
858 299 4699
US
84
Dec 3, 2020
0001797768
NASDAQ
Biotechnology
Healthcare
49705R105
US49705R1059
US
2.66
1.34
369.11k
125.46M
-
1.04-7.185
0.57
-
-
-
-
-0.96
-
https://www.kinnate.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.